Home » Stocks » ONVO

Organovo Holdings, Inc. (ONVO)

Stock Price: $6.65 USD -0.20 (-2.92%)
Updated May 13, 2021 4:00 PM EDT - Market closed
Market Cap 48.75M
Revenue (ttm) n/a
Net Income (ttm) -16.95M
Shares Out 7.12M
EPS (ttm) -2.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $6.65
Previous Close $6.85
Change ($) -0.20
Change (%) -2.92%
Day's Open 6.88
Day's Range 6.57 - 7.10
Day's Volume 114,829
52-Week Range 0.47 - 23.92

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Catherine Wood ( Trades , Portfolio )'s ARK Investment Management has revealed a large reduction in the Organovo Holdings Inc. (NASDAQ:ONVO) position alongside a small reduction in the Syros Pharmaceuti...

Other stocks mentioned: SYRS
2 months ago - GuruFocus

SOLANA BEACH, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), today announced it will be featured as a presenting company at the H.C. Wainwright Global Life Sciences C...

2 months ago - GlobeNewsWire

SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (“Organovo” or the “Company”) (Nasdaq: ONVO) announced today that it has regained compliance with the minimum bid price requiremen...

8 months ago - GlobeNewsWire

SAN DIEGO, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (the “Company”) (Nasdaq: ONVO) today announced that it filed a certificate of second amendment to its certificate of incorporation ...

8 months ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in Organovo.

1 year ago - Zacks Investment Research

Bet on these top-ranked stocks with rising P/E for outsized gains.

Other stocks mentioned: ALXN, AVGR, CYBR, QLYS
1 year ago - Zacks Investment Research

Organovo (ONVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Reiterates Commitment to Strategic Review Process Reiterates Commitment to Strategic Review Process

1 year ago - GlobeNewsWire

Organovo (ONVO) delivered earnings and revenue surprises of 0.00% and -13.13%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Organovo (ONVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Organovo (ONVO) needs investors to pay close attention to the stock based on moves in the options market lately.

1 year ago - Zacks Investment Research

Organovo Holdings, Inc. (ONVO) CEO Taylor Crouch on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

About ONVO

Organovo Holdings, Inc., a biotechnology company, develops bioprinted human tissues based on its 3D human tissue platform technology that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for... [Read more...]

Industry
Diagnostics & Research
Founded
2007
Stock Exchange
NASDAQ
Ticker Symbol
ONVO
Full Company Profile

Financial Performance

In 2019, ONVO's revenue was $2.20 million, a decrease of -28.96% compared to the previous year's $3.09 million. Losses were -$18.71 million, -29.75% less than in 2018.

Financial Statements